PIPAC with Nal-IRI

Phase 1Small molecule

UUniversity Hospital, Ghent

PIPAC with Nal-IRI is one of 81 small molecule programs targeting Intestinal Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intestinal CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Peritoneal CarcinomatosisActive, not recruiting

Intestinal CancerPhase 1

Active, not recruiting

Ovarian CancerPhase 1

Active, not recruiting

Peritoneal CarcinomatosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Phase 3

8 2

Taxotere

AAvyxa

Phase 3

11 3

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 3

4 4

Pamiparib

BeiGene

Phase 3

5 5

Sacituzumab Tirumotecan

Merck & Co.

Phase 3

1 6

SHR-A1811

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

4 7

Defactinib

VVerastem, Inc.

Phase 3

3 8

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 9

BL-B01D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

—10

In Vitro Sensitivity-Directed Chemotherapy

CChildren's Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Peritoneal Carcinomatosis

NCT05277766

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer

Completed·UUniversity Hospital, Ghent·Phase 1·NCT03304210·20 enrolled

Peritoneal Carcinomatosis1 trial

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study

Active, not recruiting·UUniversity Hospital, Ghent·Phase 1·NCT05277766·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PIPAC with Nal-IRI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PIPAC with Nal-IRI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PIPAC with Nal-IRI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Ghent company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity Hospital, Ghent

PIPAC with Nal-IRI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Ovarian Cancer1 trial

Peritoneal Carcinomatosis1 trial

References

Drug Info

Quick Facts

Related News